American Diabetes Association Archives - Medical Design Sourcing

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]

As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a number of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came …

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a range of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.<…

Study shows health equity impact from Virta Health diabetes reversal platform

Virta Health announced that real-world data for its diabetes reversal platform demonstrated narrowing gaps in care.

The company shared its data at the American Diabetes Association’s 83rd Scientific Sessions. The research highlighted its impact on health equity. It demonstrated significant health improvement and medication reduction for members in the most and least disadvantaged U.S. neighborhoods.

Virta said diabetes disproportionately affects racial and ethnic minorities and those living in low-income areas. Additionally, those with financial hardships prove more likely to receive prescriptions for diabetes drugs that are older and harder to manage due to affordability and access. With complex regimens, these lower-income patients have a higher likelihood of hospitalization and severe diabetes complications.

Get the full story at our sister site, Drug Delivery Business News.

Vida Health reports positive data for virtual diabetes program in low-income populations

[Image courtesy of Vida Health]Vida Health announced new research demonstrating significantly lowered A1C levels with its virtual cardiometabolic program.

The research highlighted use of the program in low-income Medicare Advantage members. Significantly lowered A1C levels even occurred in areas with limited income and food access.

Vida Health’s study compared its members living in areas of low income and low access to food with members living elsewhere. The study classified such low-income areas using the USDA’s Food Access Research Atlas.

Results demonstrated that, irrespective of socioeconomic barriers, Vida interventions led to an average A1C reduction of -1.38 points.

Get the full story at our sister site, Drug Delivery Business News.

Studies back Fractyl Health diabetes reversal procedure, gene therapy

Fractyl Health announced multiple studies supporting its programs for the reversal and treatment of diabetes.

Lexington, Massachusetts-based Fractyl reported data from its Revitalize 1 pivotal study and its Rejuva program. Revitalize 1 evaluates the company’s Revita endoscopic ablation procedure to reverse diabetes. Rejuva evaluates a targeted pancreatic gene therapy.

The company presented its results at the American Diabetes Association’s 83rd Scientific Sessions.

Get the full story at our sister site, Drug Delivery Business News.

Data supports safety and accuracy of Senseonics 365-day CGM

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE: SENS) today announced positive clinical data highlighting the effectiveness of its Eversense continuous glucose monitor (CGM).

Germantown, Maryland–based Senseonics presented two studies on its latest-generation Eversense E3 at the American Diabetes Association 83rd Scientific Session. The 180-day implantable CGM received FDA approval in February of last year. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.

Senseonics’ latest data includes evidence supporting even longer wear time, plus more positive results for the existing platform.

“These data further bolster Eversense’s position as a leading CGM choice for people with diabetes,” said Dr. Francine Kaufman, Senseonics chief medical officer.

Get the full story at our sister site, Drug Delivery Business News.

Abbott, ADA partner on therapeutic nutrition program for people with diabetes

The FreeStyle Libre 3 continuous glucose monitor. [Image courtesy of Abbott]Abbott (NYSE: ABT) + and the American Diabetes Association (ADA) announced a collaboration to improve nutrition for people with diabetes.

The duo aims to help better understand how diabetes technology, like continuous glucose monitoring (CGM), can help. They hope to aid people with diabetes make more informed decisions about their food and activity.

Abbott develops a family of CGMs, the latest being the FreeStyle Libre 3. The company said that, over time, data from CGMs helps people with diabetes learn patterns and create a nutritional plan. That plan can help provide steady glucose levels and the potential for improved clinical outcomes, like lower A1C.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom aims to bring new glucose sensor to the market for people who don’t use insulin

Dexcom (Nasdaq:DXCM) today unveiled its strategy to expand access to its glucose-sensing technology for millions around the world.

San Diego-based Dexcom held an Investor Day event in which it revealed plans to bring a new product to market in the U.S. in 2024. The company designed its new product for people who don’t use insulin — approximately 70% of Americans with diabetes.

Dexcom said it plans for its new product to feature a 15-day sensor and a cash-pay option. The company wants to offer a new software experience tailored for those not on insulin.

Earlier this year, Dexcom Chair, President and CEO, Kevin Sayer, hinted at potential new avenues when speaking to Drug Delivery Business News. He explained that the company wanted to broaden its focus, even revising its mission statement. Dexcom updated its mission — enabling people to take control of diabetes — by changing “diabetes” to “health.”

Abbott, American Diabetes Association partner to help people of color with diabetes

(Image courtesy of Abbott)

Abbott (NYSE:ABT) and the American Diabetes Association (ADA) announced today that they launched a joint community health partnership in Ohio.

The community initiative — the first under the ADA’s Health Equity Now platform — will launch in Columbus, Ohio, and be conducted with the National Center for Urban Solutions (NCUS) in an effort to better understand and address healthcare disparities for people with cover living with diabetes while also improving accessibility of diabetes care technology within the community.

Get the full story at our sister site, Drug Delivery Business News.

Medtronic commits to helping people of color with diabetes

Medtronic (NYSE:MDT) announced today that it entered multiple partnerships to help improve health equity for people of color living with diabetes.

Fridley, Minn.-based Medtronic committed investments in partnerships with the American Diabetes Association (ADA) and the T1D Exchange, along with additional research efforts, to better understand and address such disparities, according to a news release.

The company is providing a $1 million sponsorship over the next three years to ADA’s Technology Access Project (TAP) which sets out to provide access and availability of diabetes technology regardless of gender, race, income or location.

“Health equity in diabetes is central to our mission, and unfortunately, for many the latest technological advancements to support living with the disease are not accessible due to insurance barriers and high out-of-pocket costs,” ADA chief development officer Charles D. Henderson said in the release. “…

Abbott, Medtronic go head-to-head at ADA conference

Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology.

The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller companies as well as studies showing how diabetes tech is helping diverse patient populations. More than 800 sessions have been planned.

Here are some of the highlights of this year’s conference, which began June 12.

Next>>

Medtronic touts results of latest MiniMed studies at ADA

The latest generation of the Medtronic (NYSE:MDT) MiniMed insulin pump met both safety and glycemic endpoints in a study presented today at the American Diabetes Association’s virtual annual conference.

The MiniMed 780G closed-loop system is indicated for treating Type 1 diabetes in people aged 7 to 80 years old. It is designed to automate the delivery of both basal insulin and correction boluses every five minutes to help people with diabetes avoid highs and lows with greater ease, according to Fridley, Minn.-based Medtronic. It also enables patients to program insulin action time from two to eight hours, and has an adjustable target setting as low as 100 mg/dL. The MiniMed 780G won the CE Mark this week, but has not been approved for use in the U.S.

The 90-day at home U.S. pivotal trial included patients aged 14 to 75 years old and yielded no severe adverse events, according to the company. The trial results include:

No severe hypoglycemia and diab…